Araris Biotech AG’s Post

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/et3aqUBM

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/ez7rqXv7

Patient-specific DILI Causality Assessments using the power of the MetaHeps assay !

Didn’t catch our live webinar? Now available on-demand, this session features Curia experts, Priyanka Tripathi and Subir Sadhukhan, unveiling transformative strategies in drug discovery. Discover how our innovative scaffold and compound library design, yielding over 164,000 compounds for high-throughput screening, is designed to enhance efficiency and accelerate research. Watch now to gain valuable insights and actionable strategies from industry leaders. Access the webinar here. https://ow.ly/OaT950UjeNi #Drugdiscovery #cdmo #Chemotypes #Curiawebinar

Patient-specific DILI causality assessments in clinical studies using the power of the MetaHeps assay !

Listen to my colleague Michael J. Tarlov describe the development of the National Institute of Standards and Technology (NIST) Biomanufacturing Program, which provides the #biopharmaceutical and #biotech sectors with measurements and reference materials for their processes and product quality assurance. https://lnkd.in/eV--AAij

At WADC in London our team presented a poster showcasing our unique ThioBridge™ conjugation technology that's been proven to improve the stability, potency and efficacy of antibody-drug conjugates (#ADCs).   ThioBridge™ addresses key challenges in ADC design and development by leveraging naturally occurring interchain disulfide bonds. This results in a more uniform drug-to-antibody ratio (DAR) profile, improved linker stability and precise site-specificity, ensuring no deconjugation or cross-conjugation issues.   Biopharma developers: How might this technology impact your ADC pipeline? Let's discuss the potential for improved efficacy and safety profiles today!   Access the poster here to learn more: https://lnkd.in/eU8p5ima

Biologics/New Modalities continues to move forward at pace. Every scientist generates data, be it their idea, a paper, a project or a meeting. So, how do you capture, store, share, interact, and develop these ideas as an individual and with the wisdom of crowds ideas from your colleagues, and how to keep that data and idea alive? Have a look at LiveDesign, join the workshop and listen to the presentation to find out more.

Exciting news from Interphex!! Microfluidics has been awarded the prestigious 2024 Biotech Innovation Award on behalf of the new MP350 Microlyser™ Processor. "The Biotech Innovation Award acknowledges an exhibitor’s innovative application to a given product or service that not only addresses an industry need but does so in such a way as to exceed previous standards or applications—thereby making the given process simpler, smoother, or easier to navigate." Microlyser™ technology is a NEW revolutionary hybrid approach to cell disruption, which pairs Microfluidics' proprietary Interaction Chamber™ with a unique sanitary electric pumping system to create a production scale solution. This biopharma technology achieves maximum yields, improves product quality and delivers optimum yields in production scale cell disruption for a variety of cells including mammalian, bacterial and yeast cells. Congratulations to the team who worked tirelessly to find a production scale cell disruption solution. Stop by our booth #3421 this week and speak to our team at the Javits Center, NYC - April 16-18, 2024. INTERPHEX - "the leading global pharmaceutical and biotechnology event that fuses industry innovation with expert-led conference." Learn more about this innovative technology! https://hubs.la/Q02sSfyY0 #Interphex #Interphex2024 #Microfluidics #Celldisruptionproductionscale #productionscalesolutionforcelldisruption

Meet Quotient at Swiss Biotech Day! Quotient Sciences is a drug development and manufacturing accelerator - providing integrated programs and tailored services across the entire development pathway. They cut through silos across a range of drug development capabilities - saving precious time and money in getting drugs to patients. E Their approach is clear: ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.